Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -248.83% is 27% above its 5-year average of -341.99%, near the high end of its 5-year range (-1368.57%–53.25%).
54.74% above its 12-month average of -549.75%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1368.57%.
NET PROFIT MARGIN
-248.83%
NET PROFIT MARGIN AVG TTM
-549.75%
NET PROFIT MARGIN AVG 3Y
-506.95%
NET PROFIT MARGIN AVG 5Y
-341.99%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+54.74%
CURRENT VS 3Y AVG
+50.92%
CURRENT VS 5Y AVG
+27.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 638 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
AbCellera Biologics Inc.
Market Cap
$4.06B
Net Profit Margin
-248.83%
TTM Avg
-549.75%
3Y Avg
-506.95%
5Y Avg
-341.99%
Market Cap
$4.13B
Net Profit Margin
12.82%
TTM Avg
-6.21%
3Y Avg
-4.84%
5Y Avg
-11.63%
Market Cap
$3.96B
Net Profit Margin
1.39%
TTM Avg
-2.46%
3Y Avg
-2.37%
5Y Avg
0.86%
Market Cap
$4.35B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.36B
Net Profit Margin
-55.82%
TTM Avg
-71.50%
3Y Avg
-84.24%
5Y Avg
-84.24%
Market Cap
$4.42B
Net Profit Margin
26.65%
TTM Avg
8.56%
3Y Avg
0.11%
5Y Avg
0.58%
Market Cap
$4.43B
Net Profit Margin
-20.73%
TTM Avg
-55.30%
3Y Avg
-87.73%
5Y Avg
-105.64%
Market Cap
$3.53B
Net Profit Margin
-74.75%
TTM Avg
-1986.54%
3Y Avg
-1142.83%
5Y Avg
-820.99%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.06B | -248.83% | -549.75% | -506.95% | -341.99% |
| LivaNova PLC (LIVN)vs › | $4.13B | 12.82% | -6.21% | -4.84% | -11.63% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 1.39% | -2.46% | -2.37% | 0.86% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.35B | 0.00% | 0.00% | 0.00% | 0.00% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.36B | -55.82% | -71.50% | -84.24% | -84.24% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 26.65% | 8.56% | 0.11% | 0.58% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.43B | -20.73% | -55.30% | -87.73% | -105.64% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.53B | -74.75% | -1986.54% | -1142.83% | -820.99% |
| Celcuity Inc. (CELC)vs › | $3.54B | 0.00% | 0.00% | 0.00% | 0.00% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.69% | -12.55% | -19.61% | -21.06% |
Operating Margin
-289.0%
Net Profit Margin
-248.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1368.57% |
| 2026-03-31 | -519.12% |
| 2025-12-31 | -19.94% |
| 2025-09-30 | -637.84% |
| 2025-06-30 | -203.27% |
| 2025-03-31 | -1077.24% |
| 2024-12-31 | -677.43% |
| 2024-09-30 | -785.42% |
| 2024-06-30 | -504.30% |
| 2024-03-31 | -407.98% |
| 2023-12-31 | -513.67% |
| 2023-09-30 | -433.55% |
| 2023-06-30 | -303.58% |
| 2023-03-31 | -328.99% |
| 2022-12-31 | -138.75% |
| 2022-09-30 | 26.26% |
| 2022-06-30 | -14.78% |
| 2022-03-31 | 53.25% |
| 2021-12-31 | 43.03% |
| 2021-09-30 | -388.16% |
| 2021-06-30 | -8.40% |
| 2021-03-31 | 57.82% |
| 2020-12-31 | 56.27% |
| 2020-09-30 | -28.77% |
| 2020-06-30 | 59.70% |
| 2020-03-31 | -44.94% |
| 2019-12-31 | -51.24% |
| 2019-09-30 | 1.04% |
| 2019-06-30 | -12.22% |
| 2019-03-31 | -12.22% |
